| Keywords: |
epidermal growth factor; platelet derived growth factor; cancer chemotherapy; human cell; major clinical study; prednisone; hepatitis; drug efficacy; antineoplastic agents; prostate specific antigen; quality of life; transforming growth factor beta; thrombocytopenia; peripheral neuropathy; drug administration schedule; editorial; cancer pain; kidney failure; antineoplastic activity; prostate cancer; rash; prostatic neoplasms; drug monitoring; drug blood level; flutamide; gonadorelin derivative; hydrocortisone; blood clotting disorder; suramin; adrenal insufficiency; basic fibroblast growth factor; drug mixture; human; male; priority journal; support, non-u.s. gov't; support, u.s. gov't, p.h.s.; keratopathy
|
